Identification of CD114 Membrane Receptors as a Molecular Target in Medulloblastomas

• Published in: International journal of molecular sciences Vol. 24; no. 6; p. 5331
• Main Authors: Monteiro, Jander Moreira, Reis Ramos, Jaqueline Isadora, Teixeira e Sousa, Ian, Bighetti-Trevisan, Rayana Longo, Ribas Filho, Jurandir Marcondes, Isolan, Gustavo Rassier
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 10.03.2023; MDPI
• Subjects: Analysis; Belgium; Bladder cancer; Bone marrow; Brain cancer; Brazil; Cancer; Cancer therapies; Cerebellar Neoplasms - metabolism; Chemotherapy; Child; Classification; Gene Expression; Genes; Genetic engineering; Gliomas; Granulocytes; Humans; Medical prognosis; Medical research; Medicine, Experimental; Medulloblastoma - metabolism; Mortality; Neoplasm Recurrence, Local; Normal distribution; Pathogenesis; Prognosis; Signal Transduction; Statistical significance; Stem cells; Tumors; Belgium; Brazil; molecular targeted therapy; neurosurgery; medulloblastoma; surgical oncology
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24065331

Medulloblastomas are the most common solid tumors in children, accounting for 8–30% of pediatric brain cancers. It is a high-grade tumor with aggressive behavior and a typically b poor prognosis. Its treatment includes surgery, chemotherapy, and radiotherapy, and presents high morbidity. Significant clinical, genetic, and prognostic differences exist between its four molecular subgroups: WNT, SHH, Group 3, and Group 4. Many studies seek to develop new chemotherapeutic agents for medulloblastomas through the identification of genes whose expressions are new molecular targets for drugs, such as membrane receptors associated with cell replication. This study aimed to assess the association of CD114 expression with mortality in patients with medulloblastoma. Databases from the Medulloblastoma Advanced Genomics International Consortium (MAGIC) were analyzed, focusing on the expression of the CD114 membrane receptor in different molecular types and its possible association with mortality. Our findings showed different CD114 expressions between Group 3 and other molecular groups, as well as between the molecular subtypes SHH γ and Group 3 α and Group 3 β. There was no statistically significant difference between the other groups and subtypes. Regarding mortality, this study did not find statistical significance in the association between low and high CD114 expressions and mortality. Medulloblastoma is a heterogeneous disease with many subtype variations of its genetic and intracellular signaling pathways. Similarly to this study, which could not demonstrate different CD114 membrane receptor expression patterns between groups, others who sought to associate CD114 expression with mortality in other types of cancer failed to establish a direct association. Since many indications point to the relation of this gene with cancer stem cells (CSCs), it may be part of a more extensive cellular signaling pathway with an eventual association with tumor recurrence. This study found no direct relationship between CD114 expression and mortality in patients with medulloblastoma. Further studies are needed on the intracellular signaling pathways associated with this receptor and its gene (the CSF3R).